Table 3.
Summary of Digoxin Pharmacokinetics Before and After Roux-en-Y Gastric Bypass (mean ± SD)
| Baseline (n=9) | 3 mo (n=9) | 12 mo (n=9) | |
|---|---|---|---|
| Digoxin | |||
| Cmax, ng/ml | 3.08 ± 1.38 | 3.05 ± 0.85 | 3.41 ± 1.13 |
| Tmax, hr | 0.82 ± 0.29 | 0.50 ± 0.19a | 0.39 ± 0.15a |
| Vd/F, L | 889 ± 172 | 815 ± 279 | 811 ± 221 |
| Cl/F, L/hr | 19.9 ± 5.6 | 18.5 ± 7.2 | 17.1 ± 6.1 |
| AUC 0→Cmax, ng·hr/ml | 1.3 ± 0.6 | 1.0 ± 0.4 | 0.8 ± 0.4a |
| AUC0–4, ng·hr/ml | 5.6 ± 1.3 | 6.1 ± 1.6 | 6.3 ± 1.6 |
| AUC0–24, ng·hr/ml | 13.0 ± 2.5 | 14.6 ± 3.8 | 14.3 ± 2.9 |
| AUC0–∞ ng·hr/ml | 26.8 ± 6.7 | 30.3 ± 10.0 | 32.8 ± 11.7 |
| AUC0→Cmax/AUC0→24 (%) | 9.4 ± 3.0 | 6.5 ± 2.4a | 5.7 ± 2.4a |
AUC = area under the concentration-time curve; Cl/F = oral clearance; Cmax = peak plasma concentration; Tmax = time to peak plasma concentration; Vd/F = apparent volume of distribution.
a
p<0.05 compared with baseline.